Chris Reindel

Chris Reindel is the current Chief Business Officer at Santen. Chris has over 25 years of experience in finance, including significant experience in the pharmaceutical industry. Chris has a long history of success in financial planning and analysis, product launches, pricing strategy, and more.

Chris began their career in 1988 as an Audit Senior with Ernst & Young in the UK. Chris then moved to EY's M&A department in 1993, where they were responsible for leading the US M&A team. In 2005, they transitioned to the pharmaceutical industry, joining Genentech as Director of R&D Finance. In this role, Chris was responsible for short- and long-term financial planning within Genentech's R&D business. Chris also provided financial analysis and context to support teams going to product portfolio committees.

In 2009, Chris joined Gilead Sciences as Director, Head of Commercial FP&A. In this role, they were responsible for supporting Gilead's $6bn Americas Commercial business and was a business partner to the head of Commercial. Disease areas included Anti-Viral, Cardiovascular, Respiratory and Liver Disease. Chris was also head of the Commercial FP&A group and responsible for short and long-term planning, pricing strategy, reimbursement, co-pay programs, impact of Health Care Reform, distributor channel strategy, product launches, JVs, ERP design and implementation.

Chris has been with Santen since October 2011, where they currently serve as Chief Business Officer.

Chris Reindel has a BSc (Hons) in Business from The Manchester Metropolitan University and a bachelors from Harvard University. Chris is also certified from ICAEW in Institute of Chartered Accountants in England & Wales (ICAEW).

Chris Reindel reports to Takeshi Ito, President & CEO. Chris Reindel works with Takayuki Yamada - Head, China Business, Kazuo Koshiji - CFO & Chief Risk Officer, and Nikolaos Tripodis - Chief Strategy Officer & Chief HR, Sustainability & Administration Officer.